Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
开发多功能药物和免疫调节剂递送纳米粒子,用于治疗患有动脉粥样硬化的癌症患者
基本信息
- 批准号:10548149
- 负责人:
- 金额:$ 53.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-01 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:Acyl Coenzyme AAddressAdverse effectsAffectAortaApolipoprotein EAreaArterial Fatty StreakAtherosclerosisBindingBinding ProteinsBiocompatible MaterialsBiodistributionBiological ProcessCD44 geneCD8-Positive T-LymphocytesCD8B1 geneCT26Cancer ModelCancer PatientCardiologyCardiovascular DiseasesCardiovascular systemCause of DeathCell ProliferationCell physiologyCellsCholesterolClinicalColonColon CarcinomaColonic NeoplasmsCytotoxic T-LymphocytesDataDendritic CellsDevelopmentDiseaseDoseDrug Delivery SystemsDrug KineticsDrug TargetingEncapsulatedEngineeringFutureGoalsHigh Fat DietHumanHyaluronic AcidImmuneImmune responseImmunologicsImmunomodulatorsImmunotherapeutic agentImmunotherapyIncidenceInfiltrationInflammatoryInflammatory ResponseInvestigationLesionMC38MacrophageMalignant NeoplasmsMicrosatellite InstabilityModelingMusNanoimmunotherapyNeoplasm MetastasisOrganOutcomePatientsPeptidesPharmaceutical PreparationsPhase I Clinical TrialsPlayPropertyProteinsResearchResearch Project GrantsResistanceRoleSignal TransductionSolid NeoplasmSterol O-AcyltransferaseSymptomsSystemT-LymphocyteTherapeuticThrombosisTissuesToxic effectTranslationsTreatment EfficacyTumor TissueUnited StatesUrokinase Plasminogen Activator Receptoractivating transcription factoranti-PD-L1 antibodiesanti-PD1 antibodiesanti-tumor immune responsebiomaterial compatibilitybiophysical propertiescancer immunotherapycancer therapycell growthcell typecheckpoint therapychemotherapyclinical developmentclinical translationcolon cancer patientscomorbiditycytotoxiccytotoxic CD8 T cellsdesigneffector T cellhigh riskimmune activationimmune cell infiltrateimmune checkpointimmunoregulationimprovedimproved outcomeinhibitoririnotecanmetastatic colorectalmouse modelnanoparticlenanoparticle deliverynanoparticle drugnanotherapeuticneoantigensneoplastic cellnovelnovel therapeuticspatient derived xenograft modelphase I trialpre-clinicalpreclinical studypreventprogrammed cell death ligand 1programmed cell death protein 1responseside effectsystemic toxicitytargeted deliverytargeted treatmenttranslational goaltreatment responsetumortumor growthtumor microenvironmenttumor-immune system interactionsviscoelasticitywound healing
项目摘要
Project Summary
Cancer and cardiovascular disease are leading causes of death in the United States. Given the high percentage
of cancer patients with co-existing atherosclerosis, the development of cancer therapeutics that prevent
progression of atherosclerosis have the potential to align cancer therapy goals with favorable cardiovascular
outcomes. Hyaluronic acid (HA) has unique properties that are desirable for the development of biocompatible
and biodegradable nanoparticle drug delivery systems for both cancer and atherosclerosis. We have developed
a hyaluronic acid nanoparticle (HANP) conjugated with PD1 memetic peptides that target and block immune
checkpoint protein PD-L1 and carry the cholesterol-lowering drug Avasimibe (PD1Y-HANP/Ava). Avasimibe is a
multifunctional agent that decreases cholesterol accumulation, inhibits tumor cell growth, and enhances immune
response by activating cytotoxic T cells. We found that systemic administrations of PD1Y-HANP/Ava led to
targeted delivery into tumors and atherosclerotic plaques, inhibition of tumor growth and atherosclerosis
progression, and significant improvement in mouse survival in a dual mouse cancer and atherosclerosis model.
In this study, we hypothesize that systemic delivery of urokinase plasminogen activator receptor (uPAR), PD-
L1 and CD44 co-targeted HANP carrying Avasimibe (ATF/PD1Y-HANP/Ava) leads to the efficient delivery of the
HANP/Ava into tumors and atherosclerotic plaques, resulting in a significant anti-tumor growth effect by direct
inhibition of tumor cell proliferation, activation of cytotoxic CD8+ T cells, and pro-immune modulatory effect of
ATF/PD1Y-HANP/Ava in tumor microenvironment. We further hypothesize that delivery of targeted PD1Y-
HANP/Ava into atherosclerotic plaques decreases cholesterol-rich macrophages and infiltrating immune cells,
and thereby prevents atherosclerosis progression. To develop and validate the proposed immunotherapy, we
will first develop ATF/PD1Y-HANP/Ava and examine the efficiency of targeted delivery in metastatic mouse colon
cancer models (Aim 1). Therapeutic efficacy and immune responses following targeted PD1Y-HANP/Ava
treatment, alone or in combination with a chemotherapy drug, irinotecan, will be evaluated in the mouse cancer
models (Aim 1). We will then determine the effect of the targeted PD1Y-HANP/Ava on targeted delivery, immune
responses and therapeutic efficacy in tumor and atherosclerotic plaques in a dual mouse colon cancer and
atherosclerosis model (Aim 2). Immunological analysis of tumors and atherosclerotic plaques will allow us to
determine therapy-related changes in immune cell types and functions, especially CD8+ T cell activity. We will
then investigate the feasibility of translation in cancer patients by examining targeted delivery and direct cytotoxic
effect of the targeted PD1Y-HANP/Ava in colon cancer patient derived xenograft models (Aim 3). Finally,
pharmacokinetics, toxicity, biodistribution and systemic immune responses will be determined in mice (Aim 4).
Results of this research should provide us with preclinical data for translational development of a phase 1 clinical
trial using this novel targeted immunotherapy for metastatic colon cancer patients with comorbid atherosclerosis.
项目概要
癌症和心血管疾病是美国的主要原因。鉴于比例很高
针对同时存在动脉粥样硬化的癌症患者,开发预防癌症的治疗方法
动脉粥样硬化的进展有可能使癌症治疗目标与有利的心血管疾病保持一致
结果。透明质酸 (HA) 具有独特的特性,有利于开发生物相容性材料
以及用于癌症和动脉粥样硬化的可生物降解的纳米颗粒药物输送系统。我们开发了
与 PD1 模因肽结合的透明质酸纳米颗粒 (HANP),可靶向并阻断免疫
检查点蛋白 PD-L1 并携带降胆固醇药物 Avasimibe (PD1Y-HNP/Ava)。阿瓦西贝是一种
减少胆固醇积累、抑制肿瘤细胞生长、增强免疫力的多功能剂
通过激活细胞毒性 T 细胞做出反应。我们发现全身给予 PD1Y-HNP/Ava 会导致
靶向递送至肿瘤和动脉粥样硬化斑块,抑制肿瘤生长和动脉粥样硬化
在小鼠癌症和动脉粥样硬化双重模型中,小鼠存活率显着提高。
在这项研究中,我们假设尿激酶纤溶酶原激活剂受体(uPAR)的全身递送,PD-
L1 和 CD44 共同靶向携带 Avasimibe (ATF/PD1Y-HANP/Ava) 的 HANP 导致有效递送
HANP/Ava进入肿瘤和动脉粥样硬化斑块,直接产生显着的抗肿瘤生长作用
抑制肿瘤细胞增殖、激活细胞毒性 CD8+ T 细胞以及促免疫调节作用
肿瘤微环境中的 ATF/PD1Y-HNP/Ava。我们进一步假设靶向 PD1Y- 的递送
HANP/Ava 进入动脉粥样硬化斑块,减少富含胆固醇的巨噬细胞和浸润免疫细胞,
从而防止动脉粥样硬化的进展。为了开发和验证所提出的免疫疗法,我们
将首先开发 ATF/PD1Y-HNP/Ava 并检查转移性小鼠结肠中靶向递送的效率
癌症模型(目标 1)。靶向 PD1Y-HNP/Ava 后的治疗效果和免疫反应
单独或与化疗药物伊立替康联合治疗将在小鼠癌症中进行评估
模型(目标 1)。然后我们将确定靶向 PD1Y-HNP/Ava 对靶向递送、免疫的影响
双小鼠结肠癌和动脉粥样硬化斑块的反应和治疗效果
动脉粥样硬化模型(目标 2)。肿瘤和动脉粥样硬化斑块的免疫学分析将使我们能够
确定治疗相关的免疫细胞类型和功能变化,尤其是 CD8+ T 细胞活性。我们将
然后通过检查靶向递送和直接细胞毒性来研究癌症患者中翻译的可行性
靶向 PD1Y-HNP/Ava 在结肠癌患者衍生的异种移植模型中的效果(目标 3)。最后,
将在小鼠中确定药代动力学、毒性、生物分布和全身免疫反应(目标 4)。
这项研究的结果应该为我们提供一期临床转化开发的临床前数据
使用这种新型靶向免疫疗法治疗患有动脉粥样硬化的转移性结肠癌患者的试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
                item.title }}
{{ item.translation_title }}
- DOI:{{ item.doi }} 
- 发表时间:{{ item.publish_year }} 
- 期刊:
- 影响因子:{{ item.factor }}
- 作者:{{ item.authors }} 
- 通讯作者:{{ item.author }} 
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:{{ item.author }} 
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:{{ item.author }} 
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:{{ item.author }} 
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:{{ item.author }} 
数据更新时间:{{ patent.updateTime }}
Lily Yang其他文献
Lily Yang的其他文献
{{
              item.title }}
{{ item.translation_title }}
- DOI:{{ item.doi }} 
- 发表时间:{{ item.publish_year }} 
- 期刊:
- 影响因子:{{ item.factor }}
- 作者:{{ item.authors }} 
- 通讯作者:{{ item.author }} 
{{ truncateString('Lily Yang', 18)}}的其他基金
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
开发多功能药物和免疫调节剂递送纳米粒子,用于治疗患有动脉粥样硬化的癌症患者
- 批准号:10334547 
- 财政年份:2021
- 资助金额:$ 53.22万 
- 项目类别:
Translational Development of a Targeted and Stroma-penetrating Nanoparticle Drug for Pancreatic Cancer Therapy
用于胰腺癌治疗的靶向基质穿透纳米颗粒药物的转化开发
- 批准号:10705200 
- 财政年份:2019
- 资助金额:$ 53.22万 
- 项目类别:
Translational Development of a Targeted and Stroma-breaking Nanoparticle Drug for Pancreatic Cancer Therapy
用于胰腺癌治疗的靶向和基质破坏纳米颗粒药物的转化开发
- 批准号:9907528 
- 财政年份:2019
- 资助金额:$ 53.22万 
- 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
- 批准号:8700565 
- 财政年份:2013
- 资助金额:$ 53.22万 
- 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
- 批准号:8333962 
- 财政年份:2011
- 资助金额:$ 53.22万 
- 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
- 批准号:8518266 
- 财政年份:2011
- 资助金额:$ 53.22万 
- 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
- 批准号:8874343 
- 财政年份:2011
- 资助金额:$ 53.22万 
- 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:MR/S03398X/2 
- 财政年份:2024
- 资助金额:$ 53.22万 
- 项目类别:Fellowship 
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:2338423 
- 财政年份:2024
- 资助金额:$ 53.22万 
- 项目类别:Continuing Grant 
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:EP/Y001486/1 
- 财政年份:2024
- 资助金额:$ 53.22万 
- 项目类别:Research Grant 
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:MR/X03657X/1 
- 财政年份:2024
- 资助金额:$ 53.22万 
- 项目类别:Fellowship 
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:2348066 
- 财政年份:2024
- 资助金额:$ 53.22万 
- 项目类别:Standard Grant 
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:AH/Z505481/1 
- 财政年份:2024
- 资助金额:$ 53.22万 
- 项目类别:Research Grant 
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:10107647 
- 财政年份:2024
- 资助金额:$ 53.22万 
- 项目类别:EU-Funded 
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:2341402 
- 财政年份:2024
- 资助金额:$ 53.22万 
- 项目类别:Standard Grant 
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:10106221 
- 财政年份:2024
- 资助金额:$ 53.22万 
- 项目类别:EU-Funded 
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:AH/Z505341/1 
- 财政年份:2024
- 资助金额:$ 53.22万 
- 项目类别:Research Grant 

 刷新
              刷新
            
















 {{item.name}}会员
              {{item.name}}会员
            



